Last updated 8 days ago

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

1200 patients around the world
Available in Chile, United States
Merck Sharp & Dohme LLC
1Research sites
1200Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Non-Hodgkin Lymphoma
Small lymphocytic lymphoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Instituto Oncológico FALP - UIDO
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy